Can a patient with extensively drug‑resistant tuberculosis on delamanid, bedaquiline, cycloserine, and moxifloxacin safely undergo liver transplantation for cirrhosis?

Liver Transplantation in XDR-TB on Treatment: Proceed with Extreme Caution and Modified Regimen

Liver transplantation can be performed in patients with active XDR-TB, but requires immediate modification of the current regimen to eliminate hepatotoxic agents and prevent drug-drug interactions with immunosuppression, while maintaining adequate TB treatment efficacy.

Critical Pre-Transplant Considerations

Immediate Regimen Modification Required

Your current regimen contains cycloserine, which poses significant risks:

• Cycloserine requires dose monitoring with blood levels kept below 30 mcg/mL 1
• In renal dysfunction (common post-transplant), start with 250 mg daily and verify with therapeutic drug monitoring 2
• CNS toxicity risk increases with doses >500 mg daily 1

Bedaquiline and delamanid are the safest options for post-transplant continuation as they:

• Have no dose adjustment needed for renal dysfunction 2
• Lack significant hepatotoxicity compared to first-line agents
• Are strongly recommended for XDR-TB treatment 2

Drug-Drug Interaction Management

Critical issue: Moxifloxacin interactions with calcineurin inhibitors (CNIs)

• Both metabolized via cytochrome P450-3A4 3
• Requires close monitoring but can be continued
• Moxifloxacin is a strong recommendation for XDR-TB 2

Avoid rifamycins entirely post-transplant - they dramatically increase rejection risk (P<0.001) 4

Recommended Peri-Transplant Strategy

Phase 1: Pre-Transplant Optimization

• Confirm culture conversion status - this is essential before proceeding
• Continue current regimen until transplant if liver function permits
• Obtain baseline drug susceptibility testing including bedaquiline and linezolid resistance markers (Rv0678 mutations) 5

Phase 2: Immediate Post-Transplant Regimen

Transition to rifamycin-free, hepatotoxicity-minimized regimen:

1. Continue bedaquiline (400 mg daily × 14 days, then 200 mg 3×/week) 2
2. Continue moxifloxacin (400-600 mg daily) with CNI level monitoring 2
3. Continue delamanid (100 mg twice daily) 2
4. Modify cycloserine dosing: Start 250 mg daily with therapeutic drug monitoring, especially given post-transplant renal dysfunction risk 2, 1
5. Consider adding linezolid (600 mg daily) if not already included - conditional recommendation for XDR-TB 2

Phase 3: Duration and Monitoring

Treatment duration for XDR-TB: 15-24 months after culture conversion 2

Essential monitoring:

• Weekly drug levels for cycloserine, especially if renal function declines 1
• Monthly liver function tests
• CNI trough levels 2-3 times weekly initially
• Monthly sputum cultures
• Quarterly drug susceptibility testing to detect acquired resistance 5, 6

Evidence-Based Outcomes

Survival data from liver transplant with active TB:

• 1-year survival: 50-85% depending on disease severity 4, 7
• TB cure rate in survivors: 100% with appropriate second-line regimens 4, 8
• Rejection episodes: 19% overall, but significantly higher with rifamycin use 4

Critical success factors from case series:

• Rifamycin-sparing regimens (fluoroquinolones + ethambutol-based) 4
• Early transplantation before multi-organ failure 7
• Aggressive immunosuppression monitoring 3

Common Pitfalls to Avoid

1. Do NOT use rifamycins post-transplant - rejection risk is unacceptably high 4
2. Do NOT assume standard cycloserine dosing is safe - renal dysfunction post-transplant requires dose reduction and monitoring 1
3. Do NOT delay drug susceptibility testing - acquired resistance to bedaquiline/linezolid can emerge during treatment 5, 6
4. Do NOT use isoniazid or pyrazinamide if hepatotoxicity was the indication for transplant 4, 7

Multidisciplinary Coordination Required

• Transplant hepatology: Timing of surgery, immunosuppression management
• Infectious disease/TB specialist: Regimen optimization, resistance monitoring
• Clinical pharmacology: Drug-drug interaction management, therapeutic drug monitoring
• Transplant surgery: Surgical timing relative to TB treatment phase

Prognosis

With appropriate regimen modification, liver transplantation is feasible and can be life-saving 4, 8, 9. The key is maintaining TB treatment efficacy while avoiding hepatotoxic agents and managing drug interactions. Your current regimen of bedaquiline, delamanid, and moxifloxacin forms an excellent backbone - cycloserine requires careful dose adjustment post-transplant.

The alternative of not transplanting carries 100% mortality if acute liver failure is present, making transplantation the only viable option despite the complexity 7.